New Delhi, Dec. 2 -- Amid rising demand of weight loss therapies, Eli Lilly on Monday said that it was cutting the price of its popular obesity drug Zepbound, as it moves forward to make the medicine more accessible in line with the Trump administration's goals.

The price of single-dose vials of weight loss drug Zepbound has been reduced on Eli Lilly's direct-to-consumer platform, LillyDirect, as the company also races to compete with its rival Novo Nordisk.

In a statement on Monday, Eli Lilly said it was providing a discount of up to 20% on Zepbound, the obesity medicine.

The lowest dose vial will cost $299 a month for those who pay cash, Lilly said in a statement, a discount of about $50. The next higher dose of 5 milligrams will cos...